Polymeric drug delivery for the treatment of glioblastoma

Neuro-oncology
Scott D WaitAnthony L Asher

Abstract

Glioblastoma (GBM) remains an almost universally fatal diagnosis. The current therapeutic mainstay consists of maximal safe surgical resection followed by radiation therapy (RT) with concomitant temozolomide (TMZ), followed by monthly TMZ (the "Stupp regimen"). Several chemotherapeutic agents have been shown to have modest efficacy in the treatment of high-grade glioma (HGG), but blood-brain barrier impermeability remains a major delivery obstacle. Polymeric drug-delivery systems, developed to allow controlled local release of biologically active substances for a variety of conditions, can achieve high local concentrations of active agents while limiting systemic toxicities. Polymerically delivered carmustine (BCNU) wafers, placed on the surface of the tumor-resection cavity, can potentially provide immediate chemotherapy to residual tumor cells during the standard delay between surgery and chemoradiotherapy. BCNU wafer implantation as monochemotherapy (with RT) in newly diagnosed HGG has been investigated in 2 phase III studies that reported significant increases in median overall survival. A number of studies have investigated the tumoricidal synergies of combination chemotherapy with BCNU wafers in newly diagnosed or recurre...Continue Reading

References

Feb 1, 1992·British Journal of Cancer·E S NewlandsM H Brampton
May 23, 1991·The New England Journal of Medicine·P M Black
May 30, 1991·The New England Journal of Medicine·P M Black
Nov 1, 1990·Biomaterials·H Brem
Sep 1, 1980·Neurology·F H Hochberg, A Pruitt
Mar 5, 1996·Proceedings of the National Academy of Sciences of the United States of America·M MesnilH Yamasaki
Aug 1, 1996·Neurosurgery·A Giese, M Westphal
Oct 1, 1995·Brain Pathology·C M KrammX O Breakefield
Jun 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D D BignerM R Zalutsky
Sep 24, 1999·Radiation Oncology Investigations·X YuanJ A Williams
Jun 13, 2000·Cancer Biotherapy & Radiopharmaceuticals·X YuanJ A Williams
Jan 11, 2001·The New England Journal of Medicine·L M DeAngelis
Mar 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·June L ChanHoward M Sandler
Jun 14, 2002·Journal of Neuro-oncology·Phillip B StormJon Weingart
Jun 21, 2002·Clinical Pharmacokinetics·Alison B Fleming, W Mark Saltzman
Oct 18, 2002·Advanced Drug Delivery Reviews·Paul P WangHenry Brem
Nov 6, 2002·Journal of Neuro-oncology·Sergey V ShelegSergey A Belyaev
Mar 26, 2003·Journal of Neurosurgery·Prakash SampathJon D Weingart
May 2, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alessandro OliviUNKNOWN New Approaches to Brain Tumor Therapy CNS Consortium
Sep 4, 2003·The Cancer Journal·Ian F Parney, Susan M Chang
Jun 3, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sandrine OstermannRoger Stupp
Jul 9, 2004·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·Carsten NiederMichael Molls
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Mar 11, 2005·The New England Journal of Medicine·Monika E HegiRoger Stupp
Nov 22, 2005·Expert Opinion on Drug Delivery·Philippe MeneiJean-Pierre Benoit
Jan 24, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lili Liu, Stanton L Gerson

❮ Previous
Next ❯

Citations

Feb 3, 2016·Journal of Experimental & Clinical Cancer Research : CR·Yuanliang YanZhicheng Gong
Apr 18, 2016·Neurosurgical Review·Nancy Ann Oberheim BushMitchel S Berger
Aug 5, 2016·Brain Pathology·Guido Frosina
Nov 1, 2016·Journal of Biomaterials Science. Polymer Edition·Jie TaoMaling Gou
Mar 5, 2017·Immunological Reviews·Liliana E Lucca, David A Hafler
Aug 30, 2018·Journal of Cellular and Molecular Medicine·Hongmei LiuHairong Zheng
Jul 12, 2019·Journal of Experimental & Clinical Cancer Research : CR·Zhi-Peng WenXiao-Ping Chen
Mar 23, 2018·International Journal of Molecular Sciences·Elzbieta PawlowskaJanusz Blasiak
Mar 27, 2019·Frontiers in Materials·R Chase Cornelison, Jennifer M Munson
May 10, 2017·Molecular Cytogenetics·Steffi UrbschatRalf Ketter
Jan 21, 2021·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Xue ZhouXinli Liu
Dec 17, 2020·Pharmaceutics·Jessica I GriffithWilliam F Elmquist
Oct 19, 2017·Journal of Pharmaceutical Sciences·Nattawut LeelakanokAliasger Salem
Mar 28, 2021·Archivum Immunologiae Et Therapiae Experimentalis·Benita Ortega-BerlangaGabriela Navarro-Tovar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.